It is estimated that today 50% of cancer patients are cured and the remaining 50% are not cured, but live longer.
Avoiding tobacco use, leading a healthy lifestyle, protecting yourself from the sun and vaccination against infection by certain viruses are some fac1
HER2DX® was highlighted in Times 'Medical Care' category, which publicizes inventions that are successfully implemented in medical practice.
This Wednesday, the first episode of the second season of the ‘Information that cares for you/Information that cares’ podcast series will go live. Th1
Trial TILs001, which is open to patients with metastatic triple-negative breast cancer, is the first study to assess the safety and efficacy of TILs1
Treatment with trastuzumab deruxtecan, a combination of a targeted therapy with chemotherapy, increases progression-free survival of the disease and1
The Joan Rodés-Josep Baselga Advanced Research Contracts in Oncology and Neurodegenerative Diseases, awarded by the BBVA Foundation and Hospital Clín1
The new test, called HER2DX, analyzes RNA on 27 genes to predict survival outcomes and the likelihood that patients will respond to treatment.
A study conducted at Hospital Clínic analysed the genetic profile of more than 300 patients with solid tumours using a liquid biopsy blood test, resu1
On Thursday, 11 November, the Spanish Cancer Association (AECC) awarded the AECC 2021 Grants for Cancer Research at an event held at the organization1
